(1.08%) 5 102.96 points
(0.43%) 38 250 points
(2.08%) 15 936 points
(0.08%) $83.64
(-1.16%) $1.619
(0.28%) $2 349.10
(-0.53%) $27.21
(0.16%) $921.95
(0.33%) $0.935
(0.68%) $11.03
(0.15%) $0.800
(-0.32%) $91.87
@ $0.657
Issued: 14 Feb 2024 @ 15:30
Return: 91.93%
Previous signal: Feb 14 - 09:30
Previous signal:
Return: 6.16 %
Live Chart Being Loaded With Signals
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410, gene therapy candidate for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD...
Stats | |
---|---|
Today's Volume | 4.93M |
Average Volume | 9.39M |
Market Cap | 324.23M |
EPS | $0 ( 2024-04-02 ) |
Next earnings date | ( $-0.0600 ) 2024-05-03 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -4.85 |
ATR14 | $0.00900 (0.71%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-16 | Qamar Huma | Buy | 308 465 | Option (Right to Buy) |
2024-03-18 | Qamar Huma | Sell | 0 | Common Stock |
2023-09-15 | Breininger Michael | Buy | 0 | |
2024-01-03 | Musunuri Shankar | Sell | 180 204 | Common Stock |
2024-01-03 | Upadhyay Arun | Sell | 41 633 | Common Stock |
INSIDER POWER |
---|
65.17 |
Last 96 transactions |
Buy: 10 862 012 | Sell: 2 992 475 |
Volume Correlation
Ocugen Inc Correlation
10 Most Positive Correlations |
---|
10 Most Negative Correlations |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Ocugen Inc Correlation - Currency/Commodity
Ocugen Inc Financials
Annual | 2023 |
Revenue: | $6.04M |
Gross Profit: | $5.33M (88.34 %) |
EPS: | $-0.260 |
FY | 2023 |
Revenue: | $6.04M |
Gross Profit: | $5.33M (88.34 %) |
EPS: | $-0.260 |
FY | 2022 |
Revenue: | $0 |
Gross Profit: | $-1.07M (0.00 %) |
EPS: | $-0.360 |
FY | 2021 |
Revenue: | $0.00 |
Gross Profit: | $0.00 (0.00 %) |
EPS: | $-0.300 |
Financial Reports:
No articles found.
Ocugen Inc
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410, gene therapy candidate for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD. Ocugen, Inc. has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing; and Bharat Biotech for the commercialization of COVAXIN in the United States market. The company is headquartered in Malvern, Pennsylvania.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators